RxDoctor Payments Data

Marion Brewer

Primary Care · Bay St Louis, MSNPI 1235902859

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AstraZeneca at 25.4% of the total. That places this record below the midpoint for primary care clinicians in MS, where the typical reported total is $380.

$259in general payments, 2019–2025

Across 15 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$66
  • AbbVie$52
  • Sumitomo Pharma America, Inc.$33
  • Boston Scientific$28
  • Viatris Specialty LLC$23
  • Exact Sciences$17
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$259100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$259 in reported general payments places this provider in the 35th percentile of 80 primary care providers in Mississippi.

See all primary care providers in Mississippi

Medicare billing

Part B allowed, 2024
$803
Medicare patients
27
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol11$11,823
OzempicSemaglutide12$11,413
EliquisApixaban12$10,461
TrulicityDulaglutide11$9,153
Albuterol Sulfate HfaAlbuterol Sulfate35$718
Gabapentin63$700
Levothyroxine Sodium24$367
Atorvastatin Calcium67$363
Fluticasone Propionate14$348
Methocarbamol12$339
Diclofenac Sodium15$331
Rosuvastatin Calcium34$269
Duloxetine Hcl15$237
Metformin Hcl54$234
Ezetimibe14$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$66$11,82311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 80 primary care providers in Mississippi.

Other primary care in Bay St Louis

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →